Novo Nordisk is a healthcare company known for quality and innovation. So when the company had to expand its production capacity for a new insulin product, new suggestions were welcome – as long as the end result met its high expectations.
Using its expertise in fast-track constructions of biotech facilities, NNE Pharmaplan had a bold goal of completing the project in record time.
NNE Pharmaplan's approach was to redesign the project and divide it into many smaller projects that could be carried out separately and in parallel. Also key to a shorter construction time was a distinct use of standard components, methods and procedures, as well as state-of-the-art 3D design models.
The extent of the delivery included 108 vessels, most of them installed as part of pre-assembled units (modules). The project also benefited from a completely modularised automation system that was built and tested off-site.
Same high-quality standard
On 16 December 2004, the hand-over process was formally completed for the new plant for production of a new insulin product. The 7,000 sq.m. greenfield facility was completed in only 15½ months – from ground breaking to the start of performance qualification (PQ).
NNE Pharmaplan also helped Novo Nordisk bring the plant quickly and securely through the PQ and process validation (PV) phases, up to production start.